AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26180085
Drug: ASK1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASK1 inhibitor (GS-444217 delivered in chow) - late intervention (weeks 8-15 after STZ)
Trial: 26181029
Drug: Erlotinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib monotherapy for 13 days
Trial: 26181354
Drug: T790M-specific EGFR
RxNorm normalized name: PACIFIC OYSTER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T790M-specific EGFR inhibitor
Trial: 26183044
Drug: Neoadjuvant drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant drug therapy with oxaliplatin and capecitabine (and panitumumab for patients without KRAS, BRAF, and PIK3CA mutations)
Trial: 26183076
Drug: Nonmyeloablative related-donor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmyeloablative related-donor allo-BMT with post-transplantation rituximab and high-dose post-transplantation cyclophosphamide (PTCy)
Trial: 26185466
Drug: Extended-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release morphine sulfate with sequestered naltrexone hydrochloride (MSN)
Trial: 26185773
Drug: MOR103 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOR103 0.5 mg/kg
Trial: 26185773
Drug: MOR103 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOR103 2.0 mg/kg
Trial: 26186012
Drug: Bevacizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (5 mg/kg every two weeks or 7.5 mg/kg every three weeks) combined with modified FOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 on day 1, followed by 5-FU 2400 mg/m2 intravenous infusion over 46 hours every 2 weeks)
Trial: 26186135
Drug: Urinary inorganic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary inorganic arsenic plus methylated species (∑As) (µg/L) during pregnancy
Trial: 26186440
Drug: ART plus
RxNorm normalized name: Tri-Heart Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART plus low doses of IL-2
Trial: 26186556
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy using docetaxel, cisplatin, and fluorouracil (TPF)
Trial: 26187031
Drug: Ledipasvir and
RxNorm normalized name: Ledipasvir and Sofosbuvir Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir and sofosbuvir treatment
Trial: 26187300
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa (150 μg single injection for 7 days, followed by daily recombinant FSH/hMG)
Trial: 26187510
Drug: (90)Y-clivatuzumab tetraxetan
RxNorm normalized name: tetraxetan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (90)Y-clivatuzumab tetraxetan plus low-dose gemcitabine (Arm A)
Trial: 26190562
Drug: Allopurinol <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol < 300 mg
Trial: 26190562
Drug: Allopurinol >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol > 300 mg
Trial: 26194541
Drug: Baked milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baked milk oral immunotherapy (BM OIT) with a dose of 1.3 g/d BM protein, increased 50% monthly under medical supervision.
Trial: 26194541
Drug: Baked milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baked milk oral immunotherapy (BM OIT)
Trial: 26195184
Drug: Liraglutide 0.6
RxNorm normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, in addition to metformin
Trial: 26195220
Drug: Endothelial nitric
RxNorm normalized name: nitric oxide synthase endothelial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelial nitric oxide synthase-transfected endothelial progenitor cells (7 to 50 million cells, divided into 3 doses on consecutive days)
Trial: 26195720
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.8 mg/kg) every 3 weeks for a maximum of sixteen doses
Trial: 26196225
Drug: Ambrisentan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan (5 or 10 mg once daily)
Trial: 26196225
Drug: Ambrisentan and
RxNorm normalized name: ambrisentan and tadalafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan and tadalafil (upfront initial combination therapy)
Trial: 26196233
Drug: AMH (Antimüllerian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMH (Antimüllerian hormone)
Trial: 26197243
Drug: Energy-restricted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-restricted treatment (hypocaloric diet)
Trial: 26199039
Drug: Ridaforolimus 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus 20 mg daily (5 days/week) + MK-0752 1800 mg weekly
Trial: 26199039
Drug: Ridaforolimus 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus 30 mg daily (5 days/week) + MK-0752 1800 mg weekly
Trial: 26199392
Drug: Sequential high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential high-dose chemotherapy (HDC) with bevacizumab preceding GemDMC (cycle 1) and ICE (cycle 2)
Trial: 26199453
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) 40 mg every other week or monthly
Trial: 26201460
Drug: Ranibizumab injections
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab injections (3 injections)
Trial: 26201817
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg pyridoxine hydrochloric acid/d for 28 days
Trial: 26203353
Drug: Goal-directed fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed fluid therapy (GDFT) with arterial-based continuous stroke volume variation (SVV) monitoring
Trial: 26203353
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard fluid therapy)
Trial: 26205955
Drug: Short-course neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course neoadjuvant chemotherapy (NACT) followed by long-course chemoradiotherapy and definitive surgery, with a focus on the increase in circulating carbonic anhydrase IX (CAIX) levels above a threshold of 224 pg/ml after NACT.
Trial: 26210442
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of busulfan over 90 hours
Trial: 26210442
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of busulfan with intermittent fludarabine
Trial: 26210512
Drug: Probiotic therapy
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic therapy for four weeks in addition to standard of care
Trial: 26210682
Drug: RG7112 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7112 with new formulation under fasting condition
Trial: 26210682
Drug: RG7112 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7112 with multiple-dose administrations (4 schedules)
Trial: 26210682
Drug: High-dose consecutive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose consecutive daily dosing for 5 days
Trial: 26210682
Drug: High-dose consecutive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose consecutive daily dosing for 3 days
Trial: 26210682
Drug: Weekly dosing
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dosing schedule
Trial: 26210682
Drug: Low-dose/long-duration (20-day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose/long-duration (20-day) daily schedule
Trial: 26211987
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.8 mg/kg) administered i.v. on day 1 of a 21-day cycle for a total of 4 cycles
Trial: 26212068
Drug: DNA methylation
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA methylation and histone deacetylase inhibitors
Trial: 26213141
Drug: MK2206 (AKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK2206 (AKT inhibitor) administered orally at 200 mg once weekly in 28-day cycles up to 12 cycles; final doses included 300 mg (n=33), 250 mg (n=2), 200 mg (n=16), and 135 mg (n=8).
Trial: 26213141
Drug: MK2206 (AKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK2206 (AKT inhibitor)
Trial: 26213309
Drug: CRP level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP level of ≤10 mg/liter and MBDA score of >44
Trial: 26213309
Drug: CRP level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP level of >10 mg/liter
Trial: 26213608
Drug: Subcutaneous specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous specific immunotherapy (SCIT) with a standardized allergen extract from Olea europaea; up-dosing doses: 300, 600, 3000, 6000, and 15000SQ+ administered weekly, followed by a maintenance dose of 15000SQ+ after 2 weeks
Trial: 26217225
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) at doses of 0.3, 1, 2, or 3 μg/kg/min infused for 30 min followed by open-label administration for at least 90 min.
Trial: 26217540
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus polyglucosamine (ST + PG)
Trial: 26217540
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus placebo (ST + PL)
Trial: 26218032
Drug: Weekly prophylaxis
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly prophylaxis
Trial: 26218032
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no inhibitors observed)
Trial: 26218540
Drug: AZD8329 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8329 (single oral doses or repeat daily doses for 7-9 days)
Trial: 26218540
Drug: COMPOUND-20 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMPOUND-20 (single oral doses or repeat daily doses for 7-9 days)
Trial: 26218540
Drug: COMPOUND-20 (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMPOUND-20 (continuous cover for 7 days)
Trial: 26221138
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (50 mg/d) for 12 weeks
Trial: 26222441
Drug: Subgam (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgam (normal immunoglobulin, IgG) given weekly as a rapid subcutaneous infusion
Trial: 26222558
Drug: PLX3397 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLX3397 (1000 mg per day)
Trial: 26223436
Drug: MEDI-575 9
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-575 9 mg/kg/week
Trial: 26223436
Drug: MEDI-575 15
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-575 15 mg/kg/week
Trial: 26223436
Drug: MEDI-575 35
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-575 35 mg/kg/3-weekly
Trial: 26223436
Drug: MEDI-575 25
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-575 25 mg/kg/3-weekly
Trial: 26224101
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of parmesan cheese, a boiled egg and 300 ml of water
Trial: 26227196
Drug: Emerging disease-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerging disease-modifying treatments for aortic stenosis
Trial: 26228486
Drug: 0.03% and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% and 0.06% topical resiquimod gel
Trial: 26228971
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam radiotherapy (conformal 3D planning or intensity modulated radiotherapy) to a cumulative dose of approximately 40 Gy; systemic therapy maintained unaltered.
Trial: 26235450
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (including vitamin K antagonists and non-vitamin K oral anticoagulants)
Trial: 26235450
Drug: Oral anticoagulant-associated
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant-associated intracerebral hemorrhage
Trial: 26235848
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (n=48)
Trial: 26236506
Drug: Interferon β-1a
RxNorm normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon β-1a 44 μg or 22 μg subcutaneously three times weekly
Trial: 26239690
Drug: Concurrent antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent antipsychotic medications (including 40 mg pimavanserin daily)
Trial: 26239690
Drug: Concurrent antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent antipsychotic medications
Trial: 26242184
Drug: GLP-1RA therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GLP-1RA therapy
Trial: 26242794
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of depression as measured by the Montgomery and Asberg Depression Rating Scale (MADRS)
Trial: 26242794
Drug: Individual MADRS
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual MADRS items during treatment
Trial: 26242981
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine infusion (140-175mcg/kg/min)
Trial: 26242981
Drug: Regadenoson single-bolus
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regadenoson single-bolus administration
Trial: 26244832
Drug: Dolutegravir (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (1.0 mg/kg once daily)
Trial: 26245196
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 10 µL with 2,500 PfSPZ (n=6)
Trial: 26245196
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 50 µL with 2,500 PfSPZ (n=6)
Trial: 26245196
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 250 µL with 2,500 PfSPZ (n=6)
Trial: 26245196
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 25,000 PfSPZ (n=6)
Trial: 26245196
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 75,000 PfSPZ (n=6)
Trial: 26248353
Drug: 1g meropenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g meropenem every 8 hours as a 15-min infusion
Trial: 26248638
Drug: secukinumab 2×10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab 2×10 mg/kg intravenously followed by 3 mg/kg IV every 4 weeks
Trial: 26250067
Drug: Brexpiprazole (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole (2-4 mg/day for schizophrenia)
Trial: 26250067
Drug: Brexpiprazole (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole (1, 2, and 3 mg for MDD)
Trial: 26251214
Drug: Mock treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mock treatment with a control peptide
Trial: 26251251
Drug: SAMMPRIS medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAMMPRIS medical treatment
Trial: 26251251
Drug: WASID treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WASID treatment
Trial: 26252393
Drug: Migalastat HCl
RxNorm normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Migalastat HCl (150 mg or 450 mg) co-administered with agalsidase (0.2, 0.5, or 1.0 mg/kg)
Trial: 26252393
Drug: Agalsidase (0.2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agalsidase (0.2, 0.5, or 1.0 mg/kg) alone
Trial: 26254174
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor (letrozol, 2.5 mg/d for 3 months)
Trial: 28692407
Drug: Medication-assisted treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-assisted treatment (MAT)
Trial: 26254317
Drug: Drug-free counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free counseling
Trial: 26254317
Drug: Residential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residential treatment preference
Trial: 26254445
Drug: Hospital level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital level variation in treatment
Trial: 26254812
Drug: MET-HIT2000AB4 sandwich
RxNorm normalized name: Met
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MET-HIT2000AB4 sandwich strategy (postoperative chemotherapy, hyperfractionated craniospinal radiotherapy, and maintenance chemotherapy)
Trial: 26254812
Drug: HIT'91 maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIT'91 maintenance strategy (postoperative craniospinal radiotherapy, and maintenance chemotherapy)
Trial: 26259955
Drug: Trametinib (1.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (1.0, 2.0, or 3.0 mg once daily)
Trial: 26259955
Drug: Trametinib (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (2.0 mg once daily) in combination with gemcitabine (1000 mg/m(2))
Trial: 26259955
Drug: Trametinib monotherapy
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib monotherapy
Trial: 26261238
Drug: ropeginterferon alfa-2b
RxNorm normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ropeginterferon alfa-2b (50 to 540 µg, administered every 2 weeks)
Trial: 26261849
Drug: Docetaxel in
RxNorm normalized name: docetaxel Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel in combination with nintedanib
Trial: 26263403
Drug: ETR 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETR 400 mg plus TDF/FTC 300/200 mg once daily
Trial: 26264378
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg daily for 4 weeks of a 6-week cycle (Cohort A)
Trial: 26264378
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg daily on a continuous basis (Cohort B)
Trial: 26265463
Drug: Non-nucleotide reverse
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nucleotide reverse transcriptase inhibitor- and integrase-strand inhibitor-based cART
Trial: 26265479
Drug: PUR118 5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUR118 5.5 mg
Trial: 26265479
Drug: PUR118 11.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUR118 11.0 mg
Trial: 26265479
Drug: PUR118 2.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUR118 2.8 mg
Trial: 26265479
Drug: PUR118 high
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUR118 high dose (11.0 mg)
Trial: 26268514
Drug: Carnitine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnitine (20 mg/kg, IV) prior to IVIR
Trial: 26268514
Drug: IVIR (Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIR (Sodium ferric gluconate, [125 mg/100 ml] for 8 weeks)
Trial: 26268782
Drug: 60-min rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60-min rituximab infusion
Trial: 26268782
Drug: Standard second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard second dose infusion recommendation
Trial: 26269365
Drug: Sugar-sweetened beverage
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-sweetened beverage consumption (dose-response analysis)
Trial: 26271944
Drug: Dolutegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (50 mg once daily) with nevirapine (400 mg once daily) and abacavir/lamivudine (600/300 mg once daily)